MedCity News
DECEMBER 29, 2024
Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards. The post Navigating Virtual Prescribing Policy Changes in 2025 appeared first on MedCity News.
pharmaphorum
DECEMBER 30, 2024
BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form
Pharmaceutical Commerce
DECEMBER 30, 2024
A dive into the top articles in this sector making waves this year.
PharmaTech
DECEMBER 30, 2024
In this first of a four-part series, the authors provide an introduction to a practical approach for establishing specification equivalence. The regulatory basis and compliance examples from FDA observations and warning letters are included to support the need for an effective process.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 29, 2024
Remodel Health received $100 million in funding from Oak HC/FT and Hercules Capital. The post Remodel Health Secures Over $100M to Fuel Expansion in the ICHRA Market appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 30, 2024
The US FDA has granted approval for Bristol Myers Squibbs (BMS) Opdivo Qvantig for subcutaneous use to treat various solid tumours.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
DECEMBER 30, 2024
The use of advanced therapies using cells or genes to achieve significant leaps in medical treatment was perceived as a niche sector just a decade ago, but it has now started to garner a greater level of understanding and recognition in the pharmaceutical industry. Numerous groundbreaking advances have shown these therapies hold potential to revolutionise how we treat, and potentially cure, many conditions, including for patients with underlying genetic or cellular causes of disease that have
MedCity News
DECEMBER 30, 2024
While worries about the affordability of care are sure to persist for many Americans over the coming year, here are some other patient payment trends for providers to watch The post 2025 Trends to Watch in Patient Payments appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 30, 2024
Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma (ESCC).
PharmExec
DECEMBER 30, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
DECEMBER 30, 2024
Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan
MedCity News
DECEMBER 30, 2024
Addressing difficult-to-treat diseases and disorders, quickly, safely, and with little to no side effects is a positive boon to our overburdened health system. The post The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
Pharmacy Times
DECEMBER 28, 2024
Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Expert insights. Personalized for you.
71 
Let's personalize your content